Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Academic Medicine : Journal of the Association of American Medical Colleges|July 7, 2021
Improving Formative Feedback in the Operating Room Setting: Developing and Implementing an Initiative to Improve Feedback Quality and CultureOnyi Onuoha, Sarah J Heins, Justin T Clapp, et al.British Journal of Anaesthesia|January 25, 2020
Fostering belonging in academic anaesthesiology: faculty and department chair perspectives on supporting women anaesthesiologistsMeghan B Lane-Fall, Emily K B Gordon, Elizabeth A Valentine, et al.The British Journal of Dermatology|October 2, 2013
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom InventoryK B Gordon, A B Kimball, D Chau, et al.Ophthalmology|December 26, 2001
Ocular manifestations of leukemia: leukemic infiltration versus infectious processK B Gordon, H S Rugo, J L Duncan, et al.The British Journal of Dermatology|September 17, 2013
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasisB Zhu, E Edson-Heredia, G S Cameron, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 30, 2018
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 studyK B Gordon, A W Armstrong, C Han, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1997
IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cellsK M Nikcevich, K B Gordon, L Tan, et al.The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.The British Journal of Dermatology|February 24, 2012
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 yearsA B Kimball, K B Gordon, S Fakharzadeh, et al.BMC Medical Education|November 22, 2018
How does training in anesthesia residency shape residents' approaches to patient care handoffs? A single-center qualitative interview studyMadhavi Muralidharan, Justin T Clapp, Bridget Perrin Pulos, et al.Pageof 6